Novaliq Gmbh

Lts Lohmann Therapie-systeme Ag

Dermaliq Therapeutics, Inc.

Fluoron Gmbh

Bernhard Günther

Bastian Theisinger

Sonja Theisinger

Dieter Scherer

Anthony Pettigrew

Frank Löscher

Markus Beier

Clive G Wilson

Kirsten Eickhoff

Gesche Graf

Sonja Krösser

Annette Hüttig

Hasso Meinert

Hartmut Voss

Sandra Wiedersberg

Thomas Schlüter

Daniel Brandhorst

Wilfried Hiebl

Alice Meides

Bastian Mühling

Oliver Schlüter

Jörg Haisser

Daniela Willen

Yong-Keun; Kim

Annette HÜTTIG

Philipp Steven

Frank Loscher

Sonja Krosser

Heping Xu

Jorg Haisser

Annette Huttig

Clive Wilson

The invention relates to the use of semi-fluorinated alkanes, in particular mixed with ethanol, as solubilising agents, permeation promoters and/or enhancers for lipophilic and/or poorly skin-permeable pharmaceutical agents that are administered via a transdermal therapeutic system (TTS), and to corresponding TTSs containing such substances.

Use of semi-fluorinated alkanes in transdermal therapeutic systems

The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

Compositions comprising mixtures of semifluorinated alkanes

The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.

Stabilized antibody compositions

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Opthalmic compositions comprising F6H8

The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.

Stabilised protein compositions based on semifluorinated alkanes

The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Topical pharmaceutical composition based on semifluorinated alkanes

The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein&#x2014;the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and&#x2014;the composition is administered to the eye of a subject; and&#x2014;the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 &#x3bc;g.

Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases

The present invention provides a pharmaceutical composition comprising 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis or symptoms associated therewith. Furthermore, the present invention provides a pharmaceutical kit for the therapy of anterior or posterior blepharitis or symptoms associated therewith.

Pharmaceutical compositions for use in the therapy of blepharitis

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

Semifluorinated alkane compositions

The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.

Pharmaceutical composition for treatment of increased intraocular pressure

A pharmaceutical composition comprising a semifluorinated alkane of formula (I): F(CF2)(CH2)H, wherein n is an integer from 4 to 6, and m is an integer from 5 to 8, for use in the treatment or prevention of a disease or condition relating to an ocular surface of an eye of an individual, wherein the individual is a contact lens wearer, and wherein the contact lens is a hydro gel contact lens and the composition is administered topically to a surface of the eye of the individual before the contact lens is inserted to the eye of the individual and/or during contact lens wear and/or after the contact lens has been removed from the eye of the individual, or wherein the contact lens is a silicone hydrogel contact lens and the composition is administered topically to a surface of the eye of the individual after the contact lens has been removed from the eye of the individual.

Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions

The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.

Liquid pharmaceutical composition for the delivery of active ingredients

The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The invention further provides kits comprising such compositions.

Growing community of inventors

Dossenheim, Germany

Bernhard Günther